MedKoo Cat#: 413729 | Name: Diflucortolone (free base)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Diflucortolone (free base) is a topical glucocorticoid used in various DERMATOSES. It is absorbed through the skin, bound to plasma albumin, and may cause adrenal suppression. It is also administered as the valerate.

Chemical Structure

Diflucortolone (free base)
CAS#2607-06-9 (free base)

Theoretical Analysis

MedKoo Cat#: 413729

Name: Diflucortolone (free base)

CAS#: 2607-06-9 (free base)

Chemical Formula: C22H28F2O4

Exact Mass: 394.1956

Molecular Weight: 394.46

Elemental Analysis: C, 66.99; H, 7.16; F, 9.63; O, 16.22

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
Diflucortolone (free base); Diflucortolona; Diflucortolonum
IUPAC/Chemical Name
Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16-methyl-, (6alpha,11beta,16alpha)-
InChi Key
OGPWIDANBSLJPC-RFPWEZLHSA-N
InChi Code
InChI=1S/C22H28F2O4/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-21(15,3)22(14,24)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1
SMILES Code
C[C@@]12[C@@H](C(CO)=O)[C@H](C)C[C@@]1([H])[C@]3([H])C[C@H](F)C4=CC(C=C[C@]4(C)[C@@]3(F)[C@@H](O)C2)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 394.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hoppe G. Diflucortolone valerate. Asian experience. Drugs. 1988;36 Suppl 5:24-33. doi: 10.2165/00003495-198800365-00006. PMID: 3254827. 2: Veraldi S, Schianchi R, Esposito L, Pontini P, Nazzaro G. Treatment of postscabies prurigo with diflucortolone and chlorquinaldol in a group of African refugees. Trop Doct. 2019 Oct;49(4):268-270. doi: 10.1177/0049475519855577. Epub 2019 Jun 18. PMID: 31208292. 3: Veraldi S, Schianchi R, Pontini P, Gorani A. The association of isoconazole- diflucortolone in the treatment of pediatric tinea corporis. J Dermatolog Treat. 2018 Mar;29(2):200-201. doi: 10.1080/09546634.2017.1360988. Epub 2017 Sep 19. PMID: 28753055. 4: Cabras M, Gambino A, Broccoletti R, Lodi G, Arduino PG. Treatment of angular cheilitis: A narrative review and authors' clinical experience. Oral Dis. 2019 Aug 29. doi: 10.1111/odi.13183. Epub ahead of print. PMID: 31464357. 5: Haviv R, Capua M, Amir J, Harel L. Cutaneous polyarteritis nodosa successfully treated with topical diflucortolone valerate: a case report & review of the literature. Pediatr Rheumatol Online J. 2014 Oct 10;12:46. doi: 10.1186/1546-0096-12-46. PMID: 25328491; PMCID: PMC4200200. 6: Brunner N, Yawalkar S. A double-blind, multicenter, parallel-group trial with 0.05% halobetasol propionate ointment versus 0.1% diflucortolone valerate ointment in patients with severe, chronic atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol. 1991 Dec;25(6 Pt 2):1160-3. doi: 10.1016/0190-9622(91)70317-u. PMID: 1757609. 7: Geraldez MC, Carreon-Gavino M, Hoppe G, Costales A. Diflucortolone valerate ointment with and without occlusion in lichen simplex chronicus. Int J Dermatol. 1989 Nov;28(9):603-4. doi: 10.1111/j.1365-4362.1989.tb02538.x. PMID: 2583907. 8: Abdel-Salam FS, Mahmoud AA, Ammar HO, Elkheshen SA. Nanostructured lipid carriers as semisolid topical delivery formulations for diflucortolone valerate. J Liposome Res. 2017 Mar;27(1):41-55. doi: 10.3109/08982104.2016.1149866. Epub 2016 Mar 9. PMID: 26956098. 9: Czaika VA. Superficial dermatomycoses worldwide: multinational treatment experience with a combination of isoconazole nitrate and diflucortolone valerate. Introduction. Mycoses. 2008 Sep;51 Suppl 4:1. doi: 10.1111/j.1439-0507.2008.01604.x. PMID: 18783558. 10: Täuber U, Weiss C, Matthes H. Does salicylic acid increase the percutaneous absorption of diflucortolone-21-valerate? Skin Pharmacol. 1993;6(4):276-81. doi: 10.1159/000211150. PMID: 8198813.